Small molecule inhibition of c-MET in vitro in MB cell lines led to decreased proliferation, motility, and anchorage-independent growth (123), and treatment with an oral c-MET inhibitor (crizotinib) in vivo inhibited growth of subcutaneous MB tumor xenografts (124). This evidence concerns the gene MET and neoplasm.